Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis

Autoimmune Encephalitis Clinical Trial

— IPNSAE  

Official title:

Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis in France Between 2016 and 2018

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03957616
• Other study ID #: IPNSAE
• Status: Not yet recruiting
• Start date: May 30, 2019
• Est. completion date: July 31, 2019

Study information

• Verified date: May 2019
• Source: Hospices Civils de Lyon
• Contact: Géraldine Picard
• Phone: 4 72 35 58 42
• Email: geraldine.picard[@]chu-lyon.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to provide an estimate of the incidence of paraneoplastic neurological syndromes and autoimmune encephalitides in France between the years 2016 and 2018. The study will describe the incidence of antibody subtypes and regional variations.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 600
• Est. completion date: July 31, 2019
• Est. primary completion date: May 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Clinical diagnosis of Paraneoplastic Neurological Syndrome (PNS) or Autoimmune Encephalitis (AE) made by the referring physician to the national center for PNS and AE in Lyon between 2016 and 2018

Exclusion Criteria:

• Data on location of diagnosis missing

• Patients diagnosed out of the mainland French territory

• Patients for whom insufficient data was available

Related Conditions & MeSH terms

• Autoimmune Encephalitis
• Encephalitis
• Hashimoto Disease
• Paraneoplastic Neurological Syndrome
• Syndrome

Locations

Country	Name	City	State
France	Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence and prevalence of diagnosed Paraneoplastic Neurological Syndromes (PNS) and Autoimmune Encephalitis (AE) between 2016 and 2018.	Comparison between general population of the French counties and the cohort of PNS to calculate incidence and prevalence.	3 years
Secondary	Location (city) of diagnosis	Name of city where the diagnosis of Paraneoplastic Neurological Syndromes (PNS) or Autoimmune Encephalitis (AE) was made.	1 hour
Secondary	French general population of each counties	Person years for each region	3 years